2017
Nine‐month results of the BIOHELIX‐I clinical trial study: Evaluation of the PRO‐Kinetic Energy cobalt chromium bare‐metal stent system
Michael TT, Richardt G, Lansky A, Carney RJ, Khan MA, Shehadeh A, Zeymer U, Gupta S. Nine‐month results of the BIOHELIX‐I clinical trial study: Evaluation of the PRO‐Kinetic Energy cobalt chromium bare‐metal stent system. Catheterization And Cardiovascular Interventions 2017, 92: 1030-1039. PMID: 29271575, DOI: 10.1002/ccd.27434.Peer-Reviewed Original ResearchConceptsTarget vessel revascularizationCoronary artery diseaseIschemia-driven target vessel revascularizationBare metal stentsTarget vessel failureTVF ratePrimary endpointStent systemSymptomatic coronary artery diseaseTarget lesion revascularization rateSingle-arm clinical trialNine‐month resultsDual antiplatelet therapyLesion revascularization rateMean patient agePercutaneous coronary interventionSubset of patientsClinical trial studyPrespecified performance goalArm clinical trialCoronary stent systemDrug-eluting stentsMean lesion lengthMajority of implantsEligible patients
2010
The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, Stone GW, Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. Journal Of Invasive Cardiology 2010, 22: 2-6. PMID: 20048389.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngina, UnstableAngioplasty, Balloon, CoronaryAntibodies, MonoclonalBlood PlateletsC-Reactive ProteinDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHeparinHumansImmunoglobulin Fab FragmentsMaleMiddle AgedPilot ProjectsPlatelet AggregationPlatelet Aggregation InhibitorsStentsTime FactorsTirofibanTyrosineConceptsPercutaneous coronary interventionC-reactive proteinTarget vessel revascularizationPlatelet inhibitionCoronary interventionLevels of CRPInflammatory markers C-reactive proteinPlatelet aggregationC-reactive protein levelsDouble-blind study designEfficacy of tirofibanLower platelet inhibitionCoronary artery bypassCoronary artery revascularizationArtery revascularizationDiabetic subsetEligible patientsNonfatal MIArtery bypassHs-CRPVessel revascularizationSpearman correlation coefficient modelClinical endpointsFirst time pointTirofiban
2001
Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting
Leon M, Teirstein P, Moses J, Tripuraneni P, Lansky A, Jani S, Wong S, Fish D, Ellis S, Holmes D, Kerieakes D, Kuntz R. Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting. New England Journal Of Medicine 2001, 344: 250-256. PMID: 11172151, DOI: 10.1056/nejm200101253440402.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryBrachytherapyCombined Modality TherapyCoronary DiseaseCoronary ThrombosisDose-Response Relationship, RadiationDouble-Blind MethodFemaleGamma RaysHumansIridium RadioisotopesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPlatelet Aggregation InhibitorsRadiotherapy DosageSecondary PreventionStentsConceptsIridium-192 groupMyocardial infarctionLate thrombosisStent restenosisIridium-192Intracoronary irradiationTarget lesionsIntracoronary gamma radiation therapyMajor adverse cardiac eventsFrequency of restenosisOral antiplatelet therapyAdverse cardiac eventsComposite of deathPrimary end pointLate myocardial infarctionIntracoronary radiation therapyIncidence of deathRecurrence of restenosisGamma radiation therapyEligible patientsAngiographic restenosisAntiplatelet therapyPlacebo groupCardiac eventsCoronary angioplasty